Newer agents, notably semaglutide and tirzepatide, offer very potent, long-acting effects on weight loss
There is, however, less evidence to support the oral route, as oral sermorelin faces a barrier to absorption in the gastrointestinal tract, whose acidic environment degrades the peptide.33 Even with bioenhancing encapsulation technologies, you may end up trading efficacy for comfort
Treatment with 5-Amino-1MQ combined with diet transition produced dramatic whole-body adiposity and weight loss, rapidly normalising these measures to levels comparable to age-matched lean control animals an outcome that diet switch alone was unable to achieve in the same time frame
DPP-4 inhibitors have thereafter undergone long-term cardiovascular outcome trials, showing non-inferiority for risk of major acute cardiovascular endpoints
Phys Rev Lett 84(1):167170